M&A Deal Summary |
|
---|---|
Date | 2014-02-03 |
Target | HealthTronics |
Sector | Medical Products |
Buyer(s) | Altaris |
Sellers(s) | Endo International |
Deal Type | Divestiture |
Deal Value | 130M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Private Equity Firm |
---|---|
Founded | 2003 |
PE ASSETS | 10.0B USD |
Size | Mega |
Type | Sector Focused |
Altaris is a specialist private equity firm that targets investments in the healthcare industry. Altaris focuses its investment activity across the healthcare sector, including pharmaceuticals, medical devices, healthcare services and healthcare IT. Altaris will consider both control and non-control investment situations requiring $15 to $50 million of equity capital. Prospective investment situations include corporate carve-outs, leveraged buyouts, and growth equity/recapitalization investments. Altaris was formed in 2004 and is based in New York, New York.
DEAL STATS | # |
---|---|
Overall | 16 of 35 |
Sector (Medical Products) | 8 of 13 |
Type (Divestiture) | 1 of 5 |
State (Texas) | 1 of 4 |
Country (United States) | 15 of 33 |
Year (2014) | 2 of 2 |
Size (of disclosed) | 7 of 8 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-01-22 |
Quantum Health
Dublin, Ohio, United States Quantum Health is a consumer healthcare navigation company that delivers an unparalleled consumer experience based on empathy and trust, enabling employers to achieve industry-leading satisfaction rates and independently validated claim savings. Quantum Health’s model is based on years of consumer research and the insights learned from guiding millions of consumers and their providers through their healthcare journey. Quantum Health was founded in 1999 and is based in Dublin, Ohio. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-06-02 |
OSO BioPharmaceuticals Manufacturing
Albuquerque, New Mexico, United States OsoBio is a leading contract manufacturer of injectable pharmaceutical products. The company provides glass vial filling and lyophilization services for drugs and biologics that are either approved for commercial marketing or in clinical development. With facilities equipped to handle highly potent and toxic active pharmaceutical ingredients, OsoBio focuses on the production of products that require special or complex handling. |
Sell | $110M |
Category | Company |
---|---|
Founded | 1920 |
Sector | Medical Products |
Employees | 3,103 |
Revenue | 2.9B USD (2020) |
Endo International is a pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Endo International was incorporatted in 1920 and is based in Dublin, Ireland.
DEAL STATS | # |
---|---|
Overall | 1 of 4 |
Sector (Medical Products) | 1 of 2 |
Type (Divestiture) | 1 of 4 |
State (Texas) | 1 of 1 |
Country (United States) | 1 of 2 |
Year (2014) | 1 of 1 |
Size (of disclosed) | 2 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-08-28 |
Boca Pharmacal
Coral Springs, Florida, United States Boca Pharmacal, Inc. provides medical products like tablets and capsules. |
Buy | $225M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-06-24 |
DAVA Pharmaceuticals
Fort Lee, New Jersey, United States DAVA Pharmaceuticals Inc., a specialty pharmaceuticals company, is focused on developing and marketing a broad portfolio of pharmaceutical products. DAVA is aggressively building its product portfolio through a combination of acquisitions, strategic alliances, in-licensing transactions, partnerships and development. DAVA's headquarters is in Fort Lee, New Jersey. |
Buy | $575M |